Michael Tomsicek
Directeur/Membre du Conseil chez MILESTONE PHARMACEUTICALS INC.
Fortune : 189 500 $ au 30/04/2024
Profil
M. Michael J. Tomsicek est un directeur non exécutif indépendant chez Milestone Pharmaceuticals, Inc. et un directeur financier et comptable principal chez CRISPR Therapeutics AG. Il est membre du conseil d'administration de Milestone Pharmaceuticals, Inc. et d'Optimer Pharmaceuticals LLC. Auparavant, M. Tomsicek a occupé les postes de directeur financier, de trésorier, d'agent comptable principal et de vice-président chez ABIOMED, Inc. et de trésorier chez Cubist Pharmaceuticals, Inc. et de directeur financier du Global Ultrasound Product Group chez General Electric Healthcare Technologies, Inc. et de directeur des finances et de la planification commerciale chez Motorola Automotive & Industrial Electronics Group, ainsi que celui de directeur financier chez The Lexington. Il a également été membre du conseil d'administration de Trius Therapeutics, Inc. Il a obtenu son diplôme de premier cycle à l'université du Wisconsin et un MBA à l'université du Wisconsin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/04/2024 | 19 575 ( 0,06% ) | 165 800 $ | 30/04/2024 | |
| 15/04/2024 | 15 000 ( 0,03% ) | 23 700 $ | 30/04/2024 |
Postes actifs de Michael Tomsicek
| Sociétés | Poste | Début |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 01/04/2019 |
| ACRIVON THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/10/2022 |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Directeur/Membre du Conseil | 24/10/2013 |
Cimeio Therapeutics AG
 Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Directeur/Membre du Conseil | 03/11/2022 |
Anciens postes connus de Michael Tomsicek
| Sociétés | Poste | Fin |
|---|---|---|
| CRISPR THERAPEUTICS AG | Directeur Financier/CFO | 14/10/2021 |
| ABIOMED, INC. | Directeur Financier/CFO | 24/08/2017 |
| CUBIST PHARMACEUTICALS INC | Directeur Financier/CFO | 01/01/2015 |
General Electric Healthcare Technologies, Inc.
 General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Corporate Officer/Principal | 01/09/2010 |
The Lexington
 The Lexington Medical/Nursing ServicesHealth Services Part of The Ensign Group, Inc., The Lexington operates a 125-bed assisted living facility. The company is based in Ventura, CA. | Directeur Financier/CFO | - |
Formation de Michael Tomsicek
| University of Wisconsin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| MILESTONE PHARMACEUTICALS INC. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
General Electric Healthcare Technologies, Inc.
General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Health Services |
| Motorola Automotive & Industrial Electronics Group | |
ABIOMED, Inc.
 ABIOMED, Inc. Medical SpecialtiesHealth Technology ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA. | Health Technology |
The Lexington
The Lexington Medical/Nursing ServicesHealth Services Part of The Ensign Group, Inc., The Lexington operates a 125-bed assisted living facility. The company is based in Ventura, CA. | Health Services |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Technology Services |